{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T02:07:33Z","timestamp":1783649253964,"version":"3.55.0"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Polish Ministry of Science and Higher Education","award":["N402 268836"],"award-info":[{"award-number":["N402 268836"]}]},{"name":"Healthy Ageing Research Centre","award":["REGPOT-2012\u20132013-1"],"award-info":[{"award-number":["REGPOT-2012\u20132013-1"]}]}],"content-domain":{"domain":["psy-journal.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.psychres.2016.05.019","type":"journal-article","created":{"date-parts":[[2016,5,22]],"date-time":"2016-05-22T16:22:31Z","timestamp":1463934151000},"page":"54-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["BDNF serum levels in schizophrenic patients during treatment augmentation with sarcosine (results of the PULSAR study)"],"prefix":"10.1016","volume":"242","author":[{"given":"Dominik","family":"Strzelecki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Ka\u0142u\u017cy\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Wysoki\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.psychres.2016.05.019_bib1","doi-asserted-by":"crossref","first-page":"409","DOI":"10.4331\/wjbc.v5.i4.409","article-title":"New insight in expression, transport, and secretion of brain-derived neurotrophic factor: implications in brain-related diseases","volume":"5","author":"Adachi","year":"2014","journal-title":"World J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.psychres.2016.05.019_bib2","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0920-9964(90)90005-R","article-title":"A depression rating scale for schizophrenics","volume":"3","author":"Addington","year":"1990","journal-title":"Schizophr. Res."},{"issue":"5","key":"10.1016\/j.psychres.2016.05.019_bib3","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1464-5491.2006.01858.x","article-title":"Metabolic syndrome \u2013 a new world-wide definition. A Consensus Statement from the International Diabetes Federation","volume":"23","author":"Alberti","year":"2006","journal-title":"Diabet. Med."},{"issue":"6","key":"10.1016\/j.psychres.2016.05.019_bib4","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/1097-4547(20000615)60:6<783::AID-JNR11>3.0.CO;2-M","article-title":"Brain-derived neurotrophic factor and tyrosine kinase receptor TrkB in rat brain are significantly altered after haloperidol and risperidone administration","volume":"60","author":"Angelucci","year":"2000","journal-title":"J. Neurosci. Res."},{"issue":"2","key":"10.1016\/j.psychres.2016.05.019_bib5","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1124\/pr.111.005108","article-title":"Brain-derived neurotrophic factor and neuropsychiatric disorders","volume":"64","author":"Autry","year":"2012","journal-title":"Pharm. Rev."},{"issue":"1","key":"10.1016\/j.psychres.2016.05.019_bib6","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.pharmthera.2012.01.006","article-title":"Brain Derived Neurotrophic Factor: a novel neurotrophin involved in psychiatric and neurological disorders","volume":"134","author":"Balaratnasingam","year":"2012","journal-title":"Pharm. Ther."},{"issue":"2","key":"10.1016\/j.psychres.2016.05.019_bib7","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/2045125313507739","article-title":"Ketamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-analysis of efficacy","volume":"4","author":"Caddy","year":"2014","journal-title":"Ther. Adv. Psychopharmacol."},{"issue":"2\u20133","key":"10.1016\/j.psychres.2016.05.019_bib8","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0165-0173(99)00050-8","article-title":"Network interactions in schizophrenia \u2013 therapeutic implications","volume":"31","author":"Carlsson","year":"2000","journal-title":"Brain Res. Brain Res. Rev."},{"issue":"3","key":"10.1016\/j.psychres.2016.05.019_bib9","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.psychres.2011.01.011","article-title":"Effects of antipsychotics on the serum BDNF levels in schizophrenia","volume":"189","author":"Chen","year":"2011","journal-title":"Psychiatry Res."},{"issue":"3","key":"10.1016\/j.psychres.2016.05.019_bib10","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s00213-009-1665-6","article-title":"Decreased levels of serum brain-derived neurotrophic factor in drug-naive first-episode schizophrenia: relationship to clinical phenotypes","volume":"207","author":"Chen da","year":"2009","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.psychres.2016.05.019_bib11","doi-asserted-by":"crossref","first-page":"e9166","DOI":"10.1371\/journal.pone.0009166","article-title":"Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections","volume":"5","author":"Domenici","year":"2010","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.psychres.2016.05.019_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpsychires.2011.09.022","article-title":"The role of BDNF in the pathophysiology and treatment of schizophrenia","volume":"46","author":"Favalli","year":"2012","journal-title":"J. Psychiatr. Res."},{"issue":"6","key":"10.1016\/j.psychres.2016.05.019_bib13","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/j.1440-1819.2010.02153.x","article-title":"Improvement of schizophrenia with electroconvulsive therapy and serum brain-derived neurotrophic factor levels: Lack of association in a pilot study","volume":"64","author":"Fernandes","year":"2010","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.psychres.2016.05.019_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpsychires.2014.09.005","article-title":"Fast BDNF serum level increase and diurnal BDNF oscillations are associated with therapeutic response after partial sleep deprivation","volume":"59","author":"Giese","year":"2014","journal-title":"J. Psychiatr. Res."},{"issue":"4","key":"10.1016\/j.psychres.2016.05.019_bib15","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S0006-3223(98)00367-9","article-title":"A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia","volume":"45","author":"Goff","year":"1999","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.psychres.2016.05.019_bib16","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.eurpsy.2009.10.001","article-title":"Comparison of brain N-acetylaspartate levels and serum brain-derived neurotrophic factor (BDNF) levels between patients with first-episode schizophrenia psychosis and healthy controls","volume":"26","author":"Goto","year":"2011","journal-title":"Eur. Psychiatry"},{"issue":"9","key":"10.1016\/j.psychres.2016.05.019_bib17","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/mp.2010.88","article-title":"Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis","volume":"16","author":"Green","year":"2011","journal-title":"Mol. Psychiatry"},{"issue":"2","key":"10.1016\/j.psychres.2016.05.019_bib18","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1017\/S1461145713001119","article-title":"Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression","volume":"17","author":"Haile","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.psychres.2016.05.019_bib19","first-page":"21","article-title":"Effects of olanzapine on plasma levels of catecholamine metabolites, cytokines, and brain-derived neurotrophic factor in schizophrenic patients","volume":"22","author":"Hori","year":"2007","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"7","key":"10.1016\/j.psychres.2016.05.019_bib20","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.jpsychires.2005.11.004","article-title":"Associations between serum brain-derived neurotrophic factor levels and clinical phenotypes in schizophrenia patients","volume":"40","author":"Huang","year":"2006","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.psychres.2016.05.019_bib21","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/978-3-642-25758-2_12","article-title":"Glycine transport inhibitors in the treatment of schizophrenia","volume":"213","author":"Javitt","year":"2012","journal-title":"Handb. Exp. Pharm."},{"issue":"3","key":"10.1016\/j.psychres.2016.05.019_bib22","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0304-3940(02)00529-3","article-title":"Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets","volume":"328","author":"Karege","year":"2002","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.psychres.2016.05.019_bib23","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.drugalcdep.2014.06.043","article-title":"Serum brain-derived neurotrophic factor and nerve growth factor decreased in chronic ketamine abusers","volume":"142","author":"Ke","year":"2014","journal-title":"Drug Alcohol Depend."},{"issue":"1","key":"10.1016\/j.psychres.2016.05.019_bib24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0893-133X(94)00131-I","article-title":"Subanesthetic doses of ketamine stimulate psychosis in schizophrenia","volume":"13","author":"Lahti","year":"1995","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.psychres.2016.05.019_bib25","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0893-133X(01)00243-3","article-title":"Effects of ketamine in normal and schizophrenic volunteers","volume":"25","author":"Lahti","year":"2001","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.psychres.2016.05.019_bib26","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/JCP.0b013e31821895c1","article-title":"Reduced brain-derived neurotrophic factor serum concentrations in acute schizophrenic patients increase during antipsychotic treatment","volume":"31","author":"Lee","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.psychres.2016.05.019_bib27","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000205518","article-title":"Increased plasma brain-derived neurotropic factor, not nerve growth factor-Beta, in schizophrenia patients with better response to risperidone treatment","volume":"59","author":"Lee","year":"2009","journal-title":"Neuropsychobiology"},{"issue":"5","key":"10.1016\/j.psychres.2016.05.019_bib28","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.tins.2008.02.005","article-title":"Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia","volume":"31","author":"Lisman","year":"2008","journal-title":"Trends Neurosci."},{"issue":"4","key":"10.1016\/j.psychres.2016.05.019_bib29","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1080\/00048670701213211","article-title":"Changes in brain-derived neurotrophic factor following treatment with mifepristone in bipolar disorder and schizophrenia","volume":"41","author":"Mackin","year":"2007","journal-title":"Aust. N. Z. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.psychres.2016.05.019_bib30","first-page":"347","article-title":"Nerve growth factor and brain-derived neurotrophic factor concentrations in schizophrenia: a review","volume":"26","author":"Martinotti","year":"2012","journal-title":"J. Biol. Regul. Homeost. Agents"},{"issue":"6","key":"10.1016\/j.psychres.2016.05.019_bib31","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/sj.mp.4000730","article-title":"Cytokine and growth factor involvement in schizophrenia--support for the developmental model","volume":"5","author":"Nawa","year":"2000","journal-title":"Mol. Psychiatry"},{"issue":"8","key":"10.1016\/j.psychres.2016.05.019_bib32","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1016\/j.pnpbp.2011.09.004","article-title":"Associations of serum brain-derived neurotrophic factor with cognitive impairments and negative symptoms in schizophrenia","volume":"35","author":"Niitsu","year":"2011","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.psychres.2016.05.019_bib33","first-page":"237","article-title":"BDNF function and intracellular signaling in neurons","volume":"25","author":"Numakawa","year":"2010","journal-title":"Histol. Histopathol."},{"issue":"2","key":"10.1016\/j.psychres.2016.05.019_bib34","doi-asserted-by":"crossref","first-page":"61","DOI":"10.9758\/cpn.2012.10.2.61","article-title":"A review of brain-derived neurotrophic factor as a candidate biomarker in schizophrenia","volume":"10","author":"Nurjono","year":"2012","journal-title":"Clin. Psychopharmacol. Neurosci."},{"issue":"1\u20133","key":"10.1016\/j.psychres.2016.05.019_bib35","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.schres.2014.05.024","article-title":"The relationship between serum brain-derived neurotrophic factor (BDNF) and cardiometabolic indices in schizophrenia","volume":"157","author":"Nurjono","year":"2014","journal-title":"Schizophr. Res."},{"issue":"6","key":"10.1016\/j.psychres.2016.05.019_bib36","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0022-3956(99)00029-1","article-title":"NMDA receptor hypofunction model of schizophrenia","volume":"33","author":"Olney","year":"1999","journal-title":"J. Psychiatr. Res."},{"issue":"12","key":"10.1016\/j.psychres.2016.05.019_bib37","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/S0028-3908(98)00141-5","article-title":"Transport of brain-derived neurotrophic factor across the blood-brain barrier","volume":"37","author":"Pan","year":"1998","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.psychres.2016.05.019_bib38","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1515\/REVNEURO.2001.12.2.95","article-title":"The role of neurotrophic factors in psychostimulant-induced behavioral and neuronal plasticity","volume":"12","author":"Pierce","year":"2001","journal-title":"Rev. Neurosci."},{"issue":"4","key":"10.1016\/j.psychres.2016.05.019_bib39","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1017\/S1461145709991015","article-title":"Decreased BDNF levels in CSF of drug-naive first-episode psychotic subjects: correlation with plasma BDNF and psychopathology","volume":"13","author":"Pillai","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.psychres.2016.05.019_bib40","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1176\/ajp.156.1.145","article-title":"Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia","volume":"156","author":"Potkin","year":"1999","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.psychres.2016.05.019_bib41","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.neulet.2008.05.022","article-title":"Increased serum levels of brain-derived neurotrophic factor in chronic institutionalized patients with schizophrenia","volume":"439","author":"Reis","year":"2008","journal-title":"Neurosci. Lett."},{"issue":"2 Pt 2","key":"10.1016\/j.psychres.2016.05.019_bib42","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3109\/15622970802182733","article-title":"Reduced serum BDNF levels in patients with chronic schizophrenic disorder in relapse, who were treated with typical or atypical antipsychotics","volume":"11","author":"Rizos","year":"2010","journal-title":"World J. Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.psychres.2016.05.019_bib43","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1159\/000315438","article-title":"Association of serum brain-derived neurotrophic factor and duration of untreated psychosis in first-episode patients with schizophrenia","volume":"62","author":"Rizos","year":"2010","journal-title":"Neuropsychobiology"},{"issue":"2\u20133","key":"10.1016\/j.psychres.2016.05.019_bib44","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.schres.2011.03.011","article-title":"Association of serum BDNF levels with hippocampal volumes in first psychotic episode drug-naive schizophrenic patients","volume":"129","author":"Rizos","year":"2011","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.psychres.2016.05.019_bib45","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/hup.2271","article-title":"Single ketamine infusion in bipolar depression resistant to antidepressants: are neurotrophins involved?","volume":"28","author":"Rybakowski","year":"2013","journal-title":"Hum. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.psychres.2016.05.019_bib46","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1017\/S1461145710001471","article-title":"SSRI augmentation of antipsychotic alters expression of GABA(A) receptor and related genes in PMC of schizophrenia patients","volume":"14","author":"Silver","year":"2011","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"3","key":"10.1016\/j.psychres.2016.05.019_bib47","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/YIC.0000000000000070","article-title":"Improvement in verbal memory following SSRI augmentation of antipsychotic treatment is associated with changes in the expression of mRNA encoding for the GABA-A receptor and BDNF in PMC of schizophrenic patients","volume":"30","author":"Silver","year":"2015","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"10","key":"10.1016\/j.psychres.2016.05.019_bib48","doi-asserted-by":"crossref","first-page":"859","DOI":"10.2165\/11586650-000000000-00000","article-title":"Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia","volume":"25","author":"Singh","year":"2011","journal-title":"CNS Drugs"},{"issue":"3","key":"10.1016\/j.psychres.2016.05.019_bib49","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1503\/jpn.100048","article-title":"Decreased BDNF, trkB-TK+ and GAD67 mRNA expression in the hippocampus of individuals with schizophrenia and mood disorders","volume":"36","author":"Thompson Ray","year":"2011","journal-title":"J. Psychiatry Neurosci."},{"issue":"5","key":"10.1016\/j.psychres.2016.05.019_bib50","doi-asserted-by":"crossref","first-page":"522","DOI":"10.2174\/138161210790361452","article-title":"Strategies to enhance N-methyl-d-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis","volume":"16","author":"Tsai","year":"2010","journal-title":"Curr. Pharm. Des."},{"issue":"2\u20133","key":"10.1016\/j.psychres.2016.05.019_bib51","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.schres.2004.05.005","article-title":"Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis","volume":"72","author":"Tuominen","year":"2005","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.psychres.2016.05.019_bib52","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0920-9964(95)00013-C","article-title":"Cortical maldevelopment, anti-psychotic drugs, and schizophrenia: a search for common ground","volume":"16","author":"Weinberger","year":"1995","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.psychres.2016.05.019_bib53","first-page":"1","article-title":"Serum levels of brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3) in depressed patients with schizophrenia","author":"Wysokinski","year":"2015","journal-title":"Nord J. Psychiatry"},{"issue":"7","key":"10.1016\/j.psychres.2016.05.019_bib54","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S0028-3908(02)00043-6","article-title":"Neurotrophins induce BDNF expression through the glutamate receptor pathway in neocortical neurons","volume":"42","author":"Xiong","year":"2002","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.psychres.2016.05.019_bib55","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.brainres.2006.08.129","article-title":"Brain-derived neurotrophic factor rapidly increases NMDA receptor channel activity through Fyn-mediated phosphorylation","volume":"1121","author":"Xu","year":"2006","journal-title":"Brain Res."},{"issue":"7","key":"10.1016\/j.psychres.2016.05.019_bib56","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0024-3205(01)01461-8","article-title":"Role for brain-derived neurotrophic factor in learning and memory","volume":"70","author":"Yamada","year":"2002","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.psychres.2016.05.019_bib57","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3109\/03009734.2012.724118","article-title":"Acute administration of ketamine in rats increases hippocampal BDNF and mTOR levels during forced swimming test","volume":"118","author":"Yang","year":"2013","journal-title":"Ups. J. Med. Sci."},{"issue":"1","key":"10.1016\/j.psychres.2016.05.019_bib58","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/hup.1257","article-title":"Aripiprazole altered plasma levels of brain-derived neurotrophic factor and catecholamine metabolites in first-episode untreated Japanese schizophrenia patients","volume":"27","author":"Yoshimura","year":"2012","journal-title":"Hum. Psychopharmacol."},{"issue":"22","key":"10.1016\/j.psychres.2016.05.019_bib59","doi-asserted-by":"crossref","first-page":"10037","DOI":"10.1073\/pnas.88.22.10037","article-title":"Interplay between glutamate and gamma-aminobutyric acid transmitter systems in the physiological regulation of brain-derived neurotrophic factor and nerve growth factor synthesis in hippocampal neurons","volume":"88","author":"Zafra","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.psychres.2016.05.019_bib60","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00213-012-2643-y","article-title":"Low BDNF is associated with cognitive impairment in chronic patients with schizophrenia","volume":"222","author":"Zhang","year":"2012","journal-title":"Psychopharmacology"},{"issue":"8","key":"10.1016\/j.psychres.2016.05.019_bib61","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.biopsych.2012.04.032","article-title":"Brain-derived neurotrophic factor levels and its Val66Met gene polymorphism predict tardive dyskinesia treatment response to Ginkgo biloba","volume":"72","author":"Zhang","year":"2012","journal-title":"Biol. Psychiatry"},{"issue":"7","key":"10.1016\/j.psychres.2016.05.019_bib62","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s00439-012-1150-x","article-title":"Cognitive and serum BDNF correlates of BDNF Val66Met gene polymorphism in patients with schizophrenia and normal controls","volume":"131","author":"Zhang","year":"2012","journal-title":"Hum. Genet"}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178116301342?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178116301342?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T18:22:31Z","timestamp":1536690151000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178116301342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":62,"alternative-id":["S0165178116301342"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2016.05.019","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BDNF serum levels in schizophrenic patients during treatment augmentation with sarcosine (results of the PULSAR study)","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2016.05.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}